E-cigarettes may have been marketed as a healthier option to cigarettes, yet, a new report shows that 1 in 5 U.K. teenagers have tried them.» Read More
At the heart of Pfizer's pursuit of AstraZeneca is a shortage of products in its research pipeline, aggravated by a series of disappointing drug launches.
Merck reported better-than-expected quarterly earnings, helped by cost cuts and asset sales, but revenue came in slightly below expectations.
Today, wearable devices can monitor our health, track our diets -- and potentially save our lives. How?
Would you mind paying a fee at restaurants, supermarkets, and gas stations to help merchants offer health insurance to employees? One survey says yes.
Women who get chemotherapy for breast cancer may end up unemployed for a very long time, researchers reported on Monday.
WellPoint bet big Obamacare, and investors expect the nation's largest provider of Blue Cross plans to report large membership gains.
Shares in UK pharma group soar 15 percent on news that potential $100 billion-plus merger seems to have moved a step closer.
Bayer CEO Marijn Dekkers told CNBC he did not feel a need to make acquisitions on Monday.
Pfizer has renewed its interest in a takeover of UK rival AstraZeneca, in what would be one of the global drugs industry’s largest ever deals.
Oregon's deeply troubled state-run Obamacare exchange votes to have the federal exchange HealthCare.gov take over enrollment for residents.
The electronic cigarette industry reacted positively to proposed FDA regulations which could bring further legitimacy to the nicotine vapor devices.
The federal patient privacy watchdog obtained a $1.7 million settlement for lax data security practices from a leading health treatment provider. This may only be a taste of things to come.
It's "too early to tell" if President Barack Obama's signature health care law is successful, Aetna CEO Mark Bertolini told CNBC.
Allergan may be more effective in its defense against a hostile takeover bid by Valeant Pharmaceuticals if it makes a purchase of its own, an analyst says.
The chief executive of AstraZeneca, at the center of speculation of a $101 billion takeover, has said such large-scale deals are "often disruptive."
Novartis posted first-quarter profit that beat expectations, boosted by an exceptional gain from the sale of its blood transfusion test unit.
Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.
Gilead's net profit nearly tripled and revenue was more than $1 billion ahead of estimates, thanks to sales of a key Hepatitis C drug.
More than half the revenue from Botox comes from therapeutic, not cosmetic, use. And its potential is helping to make Allergan an attractive target.
Male doctors on average make 88 percent more in Medicare reimbursements than female physicians, according to an analysis of government data.
Get the best of CNBC in your inbox